Studies the LAMBRE device for closing the left atrial appendage in atrial fibrillation
Studies the LAMBRE device in adults with atrial fibrillation who cannot take blood thinners.
Plain-language title generated from the registry record
Registry title: Post-marketing Clinical Study of the LAMBRE System for Left Auricle Closure
Key facts
- Where
- Pessac, FranceSee the site
Where in France
- Hôpital Cardiologique de Haut LévêquePessac, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- French Cardiology Society
- Trial code
- NCT06465459
- Record updated
- 2 March 2026
- Original description
Atrial fibrillation (AF) is responsible for 15-20% of ischaemic strokes. These events are often caused by thrombus formation in the left atrium. Thromboembolic risk in AF is primarily prevented by oral anticoagulation. However, this drug-based approach has a number of limitations, the most important of which are compliance problems and, above all, the risk of haemorrhagic complications, some of which are potentially serious. Left atrial appendage closure is a therapeutic alternative for the prevention of cardioembolic risk in cases where anticoagulation is clearly contraindicated.Read full original descriptionShow less
ESCALLE : Post-marketing Clinical Study of the LambrE System for Left Auricle Closure
Atrial fibrillation (AF) is responsible for 15-20% of ischaemic strokes. These events are often caused by thrombus formation in the left atrium. Thromboembolic risk in AF is primarily prevented by oral anticoagulation. However, this drug-based approach has a number of limitations, the most important of which are compliance problems and, above all, the risk of haemorrhagic complications, some of which are potentially serious. Left atrial appendage closure is a therapeutic alternative for the prevention of cardioembolic risk in cases where anticoagulation is clearly contraindicated.
The CNEDiMTS opinion of 12 March 2019 defines that the LAMBRE, LIFETCH prosthesis, a device for transcatheter closure of the left atrial appendage, is authorised for the prevention of thromboembolic events in patients with non-valvular atrial fibrillation at high risk of thromboembolic events with a CHA2DS2-VASc score ≥ 4 and a formal and permanent contraindication to anticoagulants (validated by a multidisciplinary committee).
LAMBRE prosthesis in France are subject to a review of the results by the CNEDIMTS committee. Among the criteria analysed regarding the efficacy and safety of the device implantation, the result regarding the migration rate of the LAMBRE device will be one of the criteria enabling the Commission to decide on the appropriateness of the renewal of the registration.
Inclusion: Patient requiring a left atrial exclusion procedure according to the recommendations by the CNEDiMTS and HAS using the LAMBRE device; Age ≥18 years; Patient has been informed of the nature of the study and agrees to participate.
Exclusion: Minor patient; Patient refusing to participate in the study or unable to give informed consent (patient under guardianship, curatorship or safeguard of justice).